Pain mechanisms in sickle cell disease. Are we closer to a breakthrough?

Conran, Nicola

doi:10.3324/haematol.2022.281200

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 187 , 188 Its typical clinical feature is acute pain. 189 During the disease, complications such as stroke, 190 kidney disease, 191 acute lung injury, 192 myocardial injury, 193 arrhythmia, and sudden death may also occur. 194 Moreover, patients with SCD are susceptible to myeloid malignancies and death from diseases such as COVID‐19.…”

Section: Gene Therapy In Human Diseasesmentioning

confidence: 99%

CRISPR technology in human diseases

Feng,

Li,

Zhou

et al. 2024

MedComm

View full text Add to dashboard Cite

Gene editing is a growing gene engineering technique that allows accurate editing of a broad spectrum of gene‐regulated diseases to achieve curative treatment and also has the potential to be used as an adjunct to the conventional treatment of diseases. Gene editing technology, mainly based on clustered regularly interspaced palindromic repeats (CRISPR)–CRISPR‐associated protein systems, which is capable of generating genetic modifications in somatic cells, provides a promising new strategy for gene therapy for a wide range of human diseases. Currently, gene editing technology shows great application prospects in a variety of human diseases, not only in therapeutic potential but also in the construction of animal models of human diseases. This paper describes the application of gene editing technology in hematological diseases, solid tumors, immune disorders, ophthalmological diseases, and metabolic diseases; focuses on the therapeutic strategies of gene editing technology in sickle cell disease; provides an overview of the role of gene editing technology in the construction of animal models of human diseases; and discusses the limitations of gene editing technology in the treatment of diseases, which is intended to provide an important reference for the applications of gene editing technology in the human disease.

show abstract